Strongyloidiasis Outside Endemic Areas: Long-term Parasitological and Clinical Follow-up After Ivermectin Treatment

  title={Strongyloidiasis Outside Endemic Areas: Long-term Parasitological and Clinical Follow-up After Ivermectin Treatment},
  author={Silvia Anal{\'i}a Repetto and Paula Ruybal and Estela I. Batalla and Carlota Marcela Agudelo L{\'o}pez and Vanesa Fridman and Mariela Sierra and Marcelo V Radisic and Pablo M Bravo and Marikena Guadalupe Risso and Stella Maris González Cappa and Catalina D Alba Soto},
  journal={Clinical Infectious Diseases},
Background Strongyloides stercoralis affects 30-100 million people worldwide. The first-line therapy is ivermectin. Cure is defined as the absence of larvae by parasitological methods 1 year after treatment. To date, no longitudinal parasitological studies for longer periods of time have been conducted to confirm its cure. Here, we evaluated treatment response in long-term follow-up patients with chronic infection using parasitological and molecular methods for larvae or DNA detection… 

Figures from this paper

Molecular typing of Strongyloides stercoralis in Latin America, the clinical connection

Determination of clusters during the diagnosis could facilitate and improve the design of follow-up strategies to prevent severe reactivations of this chronic disease.

Strongyloidiasis in Children Outside the Tropics: Do We Need to Increase Awareness?

It is confirmed that strongyloidiasis is usually asymptomatic in children, However, due to the ability of the parasite to cause a life-long infection together with the risk of a severe form in case of immunosuppression, it is important to identify and treat infected children.

Strongyloidiasis: a neglected Neglected Tropical Disease (NTD)

The majority of people infected with Strongyloides stercoralis, a soil transmitted intestinal nematode, have subclinical (or asymptomatic) infections, and the use of corticosteroids and HTLV-1 infection are most commonly associated with the hyperinfection syndrome.

Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment

Current and emerging pharmacotherapeutic strategies for strongyloidiasis are highlighted and treatment protocols according to patient cohort are discussed and discussed, with a risk-benefit assessment considered for each case.

Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay

Results underline the high value of the S. stercoralis serologic assay, compared to stool examination, for screening purposes in travelers or migrants, or before onset of immunosuppressive therapy, could help to improve patient management and epidemiological knowledge.

Persistent eosinophilia among 21 historic cases of Strongyloides stercoralis infection: a case for routine follow-up and repeat treatment.

The data support the need for continued follow-up of treated individuals, particularly those with abnormal host defences who are at risk of severe forms of the disease, and four individuals who had eosinophilia more than 6 mo after treatment.

Prevalence of strongyloidiasis in the general population of the world: a systematic review and meta-analysis

The current study indicated that strongyloidiasis is still considered a health problem in many parts of the world and a comprehensive control program and improvement of public health sectors are required.

Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network (2009-2017)

Screening of patients with imported strongyloidiasis for S. stercoralis infection should be mandatory in patients coming from or had traveling to endemic areas, especially in those with immunosuppressant conditions.

Strongyloidiasis: A Neglected Tropical Disease.



Treatment strategies in controlling strongyloidiasis

Treating patients infected with S. stercoralis with ivermectin, which has been introduced for the treatment of human onchocerciasis, has been reported to be effective against strongyloidiasis, without serious side effects.

Randomized Clinical Trial on Ivermectin versus Thiabendazole for the Treatment of Strongyloidiasis

No significant difference in efficacy was observed, while side effects were far more frequent in thiabendazole arm, but efficacy of single dose is suboptimal.

High rate of strongyloidosis infection, out of endemic area, in patients with eosinophilia and without risk of exogenous reinfections.

The high frequency of strongyloidosis found in this group emphasizes the relevance of including this parasitosis among differential diagnosis in patients with eosinophilia and past risk of S. stercoralis infection to prevent disseminated infections secondary to corticoid therapy.

Comparative studies on the efficacy of three anthelminthics on treatment of human strongyloidiasis in Okinawa, Japan.

An epidemiological feature of Strongyloides infection in recent Okinawa might allow workers to evaluate the exact efficacy of the treatment for an extended period, over a year, without the possibility of reinfection from the environment.

The Laboratory Diagnosis and Follow Up of Strongyloidiasis: A Systematic Review

Sensitivity of microscopic-based techniques is not good enough, particularly in chronic infections and techniques such as Baermann or agar plate culture are cumbersome and time-consuming and several specimens should be collected on different days to improve the detection rate.

Imported strongyloidosis: a longitudinal analysis of 31 cases.

The results of this case series confirm that ivermectin is the drug of choice in treating imported strongyloidosis, and response to therapy can be assessed by serology and differential white blood count performed over 6 months after therapy.

Strongyloides stercoralis infection

The epidemiology and common symptoms of strongyloidiasis and strongyloides hyperinfection syndrome are reviewed, the appropriate investigations are discussed, and the evidence on treatment is summarised.

Efficacy of ivermectin against Strongyloides stercoralis in humans.

The results indicate that ivermectin might be useful and relatively safe for the therapy of Strongyloides stercoralis infection as an alternative to thiabendazole or mebendazoles.